Boston Scientific Corporation
Boston Scientific Corporation Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management said on revenue, margins and capex.
What the Q2 FY26 call signalled
2 of 4 strong
The short version
- Full year 2026 organic revenue growth guidance: 6.5% to 8.0% (Page 5). - Second quarter 2026 organic revenue growth guidance: 5.0% to 7.0% (Page 5). - WATCHMAN global growth expected at mid-teens in 2026; U.S. - Full year 2026 adjusted EPS guidance is $3.34 to $3.41, representing 9% to 11% growth versus 2025.
From Boston Scientific Corporation's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- Full year 2026 organic revenue growth guidance: 6.5% to 8.0% (Page 5).
- Second quarter 2026 organic revenue growth guidance: 5.0% to 7.0% (Page 5).
- WATCHMAN global growth expected at mid-teens in 2026; U.S. WATCHMAN growth low to mid-teens with international growth over 20% (Page 12).
- EP business organic sales grew 22% in Q1, with continued strong growth internationally; 2026 global EP anticipated growth around 10% (Page 4).
- Urology full year organic growth expected low to mid-single digits due to challenges early in the year, but anticipated improvement as the year progresses (Page 4).
- MedSurg expected to be slightly lighter in 2026 but improving into 2027 (Page 10).
2 more points from Boston Scientific Corporation's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Boston Scientific Corporation said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Boston Scientific recently closed the acquisition of Valencia Technologies to complement its Urology business.
- They expect the announced acquisition of Penumbra to close in the second half of 2026, which is a significant strategic investment.
- The company is making commercial investments, particularly focused on WATCHMAN, EP, and other key product lines.
- Investment in R&D continues with a strong pipeline, including next-generation catheters and mapping technology (e.g., FARAPULSE, FANAFLEX).
- Capital expenditures in Q1 2026 were $177 million, with a focus on operating activities and efficiency initiatives.
- They plan to maintain strategic tuck-in M&A as a top capital allocation priority, followed by share repurchases.
2 more points from Boston Scientific Corporation's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Boston Scientific Corporation said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Boston Scientific Corporation said on order book & pipeline — free account, 30 seconds.
Continue your research
Others in Health Care Equipment and Supplies this season
- Insulet Corporation (Q2 FY26)
Insulet Corporation Q2 FY26 quarterly results analysis. Full year 2026 total company revenue growth guidance raised to 21%-23%; Omnipod revenue growth of 22%-24
- Globus Medical, Inc. (Q2 FY26)
Globus Medical, Inc. Q2 FY26 quarterly results analysis. U.S. Market Cap $11,192, P/E 19.9. AI-powered earnings insights.
- Align Technology, Inc. (Q2 FY26)
Align Technology, Inc. Q2 FY26 quarterly results analysis. Worldwide revenue growth for full-year 2026 is expected to be up 3% to 4% year-over-year. Market Cap
- Solventum Corporation (Q2 FY26)
Solventum Corporation Q2 FY26 quarterly results analysis. Expectation of improved growth in 2026 compared to 2025, supporting trajectory toward LRP targets (Pag
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Boston Scientific Corporation and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Boston Scientific Corporation Q2 FY26 results?
- Full year 2026 organic revenue growth guidance: 6.5% to 8.0% (Page 5). - Second quarter 2026 organic revenue growth guidance: 5.0% to 7.0% (Page 5). - WATCHMAN global growth expected at mid-teens in 2026; U.S. - Full year 2026 adjusted EPS guidance is $3.34 to $3.41, representing 9% to 11% growth versus 2025.
What is Boston Scientific Corporation share price analysis?
Boston Scientific Corporation currently shows a neutral. The stock trades at a P/E of 24.1 with a market cap of $72,995. Investors should review the full earnings analysis for detailed insights.
Is Boston Scientific Corporation planning capital expenditure?
- Boston Scientific recently closed the acquisition of Valencia Technologies to complement its Urology business.
Keep Boston Scientific Corporation on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.